Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

<p><strong>Background:</strong> Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-19 antiviral treatments, but their antiviral activities in patients have not been compared directly. The aim of this ongoing platform trial is to compare different antivir...

Full description

Bibliographic Details
Main Authors:	Schilling, WHK, Jittamala, P, Watson, JA, Boyd, S, Luvira, V, Siripoon, T, Ngamprasertchai, T, Batty, EM, Cruz, C, Callery, JJ, Singh, S, Saroj, M, Kruabkontho, V, Ngernseng, T, Tanglakmankhong, N, Tubprasert, J, Abdad, MY, Madmanee, W, Kouhathong, J, Suwannasin, K, Pagornrat, W, Piaraksa, N, Hanboonkunupakarn, P, Hanboonkunupakarn, B, Poovorawan, K, Potaporn, M, Srisubat, A, Loharjun, B, Taylor, WRJ, Chotivanich, V, Chotivanich, K, Imwong, M, Pukrittayakamee, S, Dondorp, AM, Day, NPJ, Teixeira, MM, Piyaphanee, W, Phumratanaprapin, W, White, NJ
Other Authors:	PLATCOV Collaborative Group
Format:	Journal article
Language:	English
Published:	Elsevier 2023

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

Similar Items